RMR Wealth Builders 13F: Adds $556K to GILD Stake

RMR Wealth Builders increased its stake in Gilead Sciences, Inc. GILD by 3,730 shares during the third quarter, according to a Form 13F filing with the SEC on October 22, 2026. The purchase lifted the firm's total holdings by 9.5% to 42,950 shares. The reported value of the position reached approximately $6.4 million.

GILD Gilead Sciences, Inc.

$156.70 ▲ +31.18% year to date

1M 3M YTD

Daily close · Oct 22, 2026

What Changed in RMR Wealth Builders's Gilead Sciences Position

The fund expanded its investment by picking up 3,730 shares, bringing its total count to 42,950 shares compared to 39,220 shares previously. The 9.5% increase raised the value of the portfolio holding to $6.4 million based on disclosures filed with regulatory authorities.

Other Institutional Activity in Gilead Sciences

Other institutional investors also adjusted their positions in the drug maker during recent filing windows. CWA Asset Management Group grew its holdings by 15,240 shares, ending with 78,639 shares worth about $11.7 million. ARS Wealth Advisors Group opened a new position with 1,458 shares valued at $217,280. Caisse de Depot Et Placement Du Quebec boosted its stake by 594,774 shares to hold 1,544,223 shares valued at about $195.1 million. Massachusetts Financial Services lifted its investment by 2,058,305 shares to reach 6,281,609 shares worth roughly $799.2 million. Meanwhile, AMF Tjanstepension reduced its stake by 521,261 shares, a 96.1% drop that left it with 21,001 shares valued at $3.1 million.

Gilead Sciences, Inc. Stock Down 1.7%

Gilead Sciences, Inc. shares recently traded around $153.57, down about 2.3% from the closing price of $157.19 on October 22, 2026. The stock trades near the top of its 52-week range of $114.02 to $160.51, sitting above its 50-day moving average of $147.23 and its 200-day moving average of $138.18.

Recent Earnings

The healthcare company reported trailing twelve-month revenue of $30.5 billion with an earnings per share loss of $2.65. The company posts its next financial results on October 29, 2026.

Dividend

The firm pays an annual dividend of $3.28 per share, which translates to a dividend yield of 2.14% based on recent trading levels.

Insider Buying and Selling at Gilead Sciences, Inc.

Company insiders executed several planned stock transactions under Rule 10b5-1 trading plans during recent months. Chief Comm & Corp Aff Officer Johanna Mercier sold 3,000 shares on October 15, 2026, at a price of $156.22 per share for a total value of $468,660. Chief Financial Officer Andrew D Dickinson also sold 3,000 shares on October 15, 2026, at $156.22 per share for $468,660. Earlier in the year, Mercier sold 3,000 shares on June 15, 2026, at $123.92 per share, while Dickinson sold 3,000 shares on the same day at $125.40 per share.

Analysts Set New Price Targets

Wall Street firms updated their outlooks on the stock through October 2026. Truist Securities maintained a buy rating on October 7 with a target of $158.00. JP Morgan maintained an overweight rating on October 7 with a target of $170.00. RBC Capital maintained a sector perform rating on October 8 with a target of $126.00. Cantor Fitzgerald reiterated an overweight rating on October 8 with a target of $155.00. B of A Securities maintained a buy rating on October 20 with a target of $172.00. The stock carries a consensus buy recommendation from 26 analysts with a mean price target of $160.15.

About Gilead Sciences

Gilead Sciences, Inc. is a Foster City, California-based biopharmaceutical company that discovers, develops, and commercializes medicines for serious medical conditions. Its product portfolio features therapies for HIV-1 infection such as Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo, serving patients across the United States, Europe, and international markets.

Bottom Line

Institutional interest in Gilead Sciences remains active as market participants track upcoming earnings results scheduled for late October. Observers will monitor subsequent SEC filings to see if institutional accumulation continues at these price levels.